Dennis Bullock, MD
Family Medicine · Watkinsville, GANPI 1518995885
Payments from drug & device makers
Across 111 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$484
- Novo Nordisk$236
- Boehringer Ingelheim$176
- Sanofi-aventis U.S. LLC$162
- Amgen$124
- GSK$91
- plus $659 from 21 others
What the payments were for
- Food & beverage$1,91199%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $484 |
| Novo Nordisk | 16 | $236 |
| Boehringer Ingelheim | 12 | $176 |
| Sanofi-aventis U.S. LLC | 11 | $162 |
| Amgen | 7 | $124 |
| GSK | 3 | $91 |
| Esperion Therapeutics, Inc. | 1 | $75 |
| AbbVie(2 entities) | 5 | $71 |
| Lucid Diagnostics Inc. | 1 | $67 |
| Avanir Pharmaceuticals, Inc. | 3 | $61 |
| Lilly USA, LLC | 4 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Johnson & Johnson | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Bayer | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Alkermes, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Pfizer | 1 | $12 |
How this compares
$1,932 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 152 | $214,713 |
| EliquisApixaban | 131 | $133,692 |
| OzempicSemaglutide | 101 | $113,715 |
| FarxigaDapagliflozin Propanediol | 76 | $86,690 |
| XareltoRivaroxaban | 84 | $71,292 |
| JardianceEmpagliflozin | 56 | $70,792 |
| JanuviaSitagliptin Phosphate | 82 | $58,400 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $38,218 |
| Repatha SureclickEvolocumab | 29 | $27,770 |
| TrulicityDulaglutide | 13 | $24,737 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $15,427 |
| MyrbetriqMirabegron | 23 | $15,380 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,257 |
| Lagevrio (Eua)Molnupiravir | 23 | $11,626 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $53 | $239,450165 claims |
| PfizerEliquis | $12 | $133,692131 claims |
| Novo NordiskOzempic | $236 | $113,715101 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $176 | $88,72893 claims |
| AstraZenecaFarxiga | $484 | $86,69076 claims |
| Johnson & JohnsonXarelto | $35 | $71,29284 claims |
| MerckJanuvia, Lagevrio (Eua) | $13 | $70,026105 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $91 | $37,74080 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $15,38023 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $39 | $15,01434 claims |
| Esperion Therapeutics, Inc.Nexletol | $75 | $8,71119 claims |
| AbbVieSynthroid | $71 | $4,31664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Watkinsville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.